CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 254 filers reported holding CRISPR THERAPEUTICS AG in Q4 2019. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $768,000 | +389.2% | 12,608 | +229.4% | 0.01% | +400.0% |
| Q3 2019 | $157,000 | +17.2% | 3,828 | +34.1% | 0.00% | 0.0% |
| Q2 2019 | $134,000 | -32.0% | 2,855 | -48.3% | 0.00% | -50.0% |
| Q1 2019 | $197,000 | +50.4% | 5,526 | +20.8% | 0.00% | +100.0% |
| Q4 2018 | $131,000 | -69.3% | 4,576 | -52.5% | 0.00% | -75.0% |
| Q3 2018 | $427,000 | -9.3% | 9,630 | +20.1% | 0.00% | -33.3% |
| Q2 2018 | $471,000 | +756.4% | 8,021 | +571.8% | 0.01% | +500.0% |
| Q1 2018 | $55,000 | +111.5% | 1,194 | +8.5% | 0.00% | – |
| Q4 2017 | $26,000 | +62.5% | 1,100 | +22.2% | 0.00% | – |
| Q3 2017 | $16,000 | +14.3% | 900 | 0.0% | 0.00% | – |
| Q2 2017 | $14,000 | +100.0% | 900 | +200.0% | 0.00% | – |
| Q1 2017 | $7,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |